Decreased cardiac output.
Decreased renal perfusion and reduced urine output.
Decreased tissue perfusion, resulting in necrosis and/or lactic acidosis.
Tissue necrosis after extravasation.
Anxiety, restlessness, tremor, and headache.
Anaphylaxis induced by bisulfite preservatives in patients with hypersensitivity to sulfites.
Use in pregnancy. FDA Category C (indeterminate). This does not preclude its short-term use for a seriously symptomatic patient (See Introduction in Section III).